Clinical Trial Update: Evaluation of MTA Versus Biodentine as Pulpotomy Agents in Immature First Permanent Molars [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial comparing mineral trioxide aggregate (MTA) and Biodentine as pulpotomy agents in immature first permanent molars with carious pulp expo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dental Caries
• Pulp Exposure
• Pulpitis

Drugs mentioned

• Biodentine (tricalcium silicate cement)
• MTA (mineral trioxide aggregate)

Snippet

Sponsor: Gihan M Abuelniel ,PhD | Conditions: Carious Exposure of Pulp | Phase 1, Phase 2 | Status: COMPLETED